OBJECTIVE: To evaluate plasma 8-hydroxy-deoxy-guanosine (8OHdG) levels as a potential biomarker of premanifest and early Huntington disease (HD). METHODS: Personnel from 2 independent laboratories quantified 8OHdG in blinded longitudinal plasma samples taken 24 months apart from 160 TRACK-HD participants, as well as samples containing control plasma with added ("spiked") 8OHdG. One laboratory used a liquid chromatography-electrochemical array (LCECA) assay, and the other used liquid chromatography-mass spectrometry (LCMS). RESULTS: The LCMS assay was more accurate than the LCECA assay for measurements of "spiked" 8OHdG levels in plasma. Neither assay demonstrated cross-sectional differences in plasma 8OHdG among controls, premanifest HD, and early symptomatic HD. Similarly, neither assay showed longitudinal changes in any disease group over 24 months. CONCLUSIONS: Plasma concentration of 8OHdG is not a biomarker of disease state or progression in HD. We recommend that future putative biomarker studies use blinded sample analysis, standard curves, independent analytical methods, and strict quality control of sample collection and storage.
OBJECTIVE: To evaluate plasma 8-hydroxy-deoxy-guanosine (8OHdG) levels as a potential biomarker of premanifest and early Huntington disease (HD). METHODS: Personnel from 2 independent laboratories quantified 8OHdG in blinded longitudinal plasma samples taken 24 months apart from 160 TRACK-HD participants, as well as samples containing control plasma with added ("spiked") 8OHdG. One laboratory used a liquid chromatography-electrochemical array (LCECA) assay, and the other used liquid chromatography-mass spectrometry (LCMS). RESULTS: The LCMS assay was more accurate than the LCECA assay for measurements of "spiked" 8OHdG levels in plasma. Neither assay demonstrated cross-sectional differences in plasma 8OHdG among controls, premanifest HD, and early symptomatic HD. Similarly, neither assay showed longitudinal changes in any disease group over 24 months. CONCLUSIONS: Plasma concentration of 8OHdG is not a biomarker of disease state or progression in HD. We recommend that future putative biomarker studies use blinded sample analysis, standard curves, independent analytical methods, and strict quality control of sample collection and storage.
Authors: J B Schulz; T Dehmer; L Schöls; H Mende; C Hardt; M Vorgerd; K Bürk; W Matson; J Dichgans; M F Beal; M B Bogdanov Journal: Neurology Date: 2000-12-12 Impact factor: 9.910
Authors: Sarah J Tabrizi; Ralf Reilmann; Raymund A C Roos; Alexandra Durr; Blair Leavitt; Gail Owen; Rebecca Jones; Hans Johnson; David Craufurd; Stephen L Hicks; Christopher Kennard; Bernhard Landwehrmeyer; Julie C Stout; Beth Borowsky; Rachael I Scahill; Chris Frost; Douglas R Langbehn Journal: Lancet Neurol Date: 2011-12-02 Impact factor: 44.182
Authors: Julie C Stout; Jane S Paulsen; Sarah Queller; Andrea C Solomon; Kathryn B Whitlock; J Colin Campbell; Noelle Carlozzi; Kevin Duff; Leigh J Beglinger; Douglas R Langbehn; Shannon A Johnson; Kevin M Biglan; Elizabeth H Aylward Journal: Neuropsychology Date: 2011-01 Impact factor: 3.295
Authors: S E Browne; A C Bowling; U MacGarvey; M J Baik; S C Berger; M M Muqit; E D Bird; M F Beal Journal: Ann Neurol Date: 1997-05 Impact factor: 10.422
Authors: Elizabeth H Aylward; Peggy C Nopoulos; Christopher A Ross; Douglas R Langbehn; Ronald K Pierson; James A Mills; Hans J Johnson; Vincent A Magnotta; Andrew R Juhl; Jane S Paulsen Journal: J Neurol Neurosurg Psychiatry Date: 2010-09-30 Impact factor: 10.154
Authors: K Gmitterová; U Heinemann; J Gawinecka; D Varges; B Ciesielczyk; P Valkovic; J Benetin; I Zerr Journal: Neurodegener Dis Date: 2009-12-03 Impact factor: 2.977
Authors: Christopher A Ross; Elizabeth H Aylward; Edward J Wild; Douglas R Langbehn; Jeffrey D Long; John H Warner; Rachael I Scahill; Blair R Leavitt; Julie C Stout; Jane S Paulsen; Ralf Reilmann; Paul G Unschuld; Alice Wexler; Russell L Margolis; Sarah J Tabrizi Journal: Nat Rev Neurol Date: 2014-03-11 Impact factor: 42.937
Authors: Andrew G Hoss; Valentina N Lagomarsino; Samuel Frank; Tiffany C Hadzi; Richard H Myers; Jeanne C Latourelle Journal: Mov Disord Date: 2015-11-17 Impact factor: 10.338
Authors: Irene Ciancarelli; Daniela De Amicis; Caterina Di Massimo; Giorgio Sandrini; Caterina Pistarini; Antonio Carolei; Maria Giuliana Tozzi Ciancarelli Journal: Funct Neurol Date: 2015 Jan-Mar
Authors: Herminia D Rosas; Gheorghe Doros; Sona Gevorkian; Keith Malarick; Martin Reuter; Jean-Philippe Coutu; Tyler D Triggs; Paul J Wilkens; Wayne Matson; David H Salat; Steven M Hersch Journal: Neurology Date: 2014-02-07 Impact factor: 9.910
Authors: Lauren M Byrne; Filipe B Rodrigues; Kaj Blennow; Alexandra Durr; Blair R Leavitt; Raymund A C Roos; Rachael I Scahill; Sarah J Tabrizi; Henrik Zetterberg; Douglas Langbehn; Edward J Wild Journal: Lancet Neurol Date: 2017-06-07 Impact factor: 44.182
Authors: Georgina Askeland; Marie Rodinova; Hana Štufková; Zaneta Dosoudilova; Monika Baxa; Petra Smatlikova; Bozena Bohuslavova; Jiri Klempir; The Duong Nguyen; Anna Kuśnierczyk; Magnar Bjørås; Arne Klungland; Hana Hansikova; Zdenka Ellederova; Lars Eide Journal: Dis Model Mech Date: 2018-10-24 Impact factor: 5.758